MacroGenics Inc MGNX:NASDAQ

Last Price$30.68Cboe Real-Time Last Sale as of 1:10PM ET 7/13/20
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+0.16(0.52%)
Bid (Size)$30.69 (102)
Ask (Size)$30.86 (100)
Day Low / High$29.76 - 31.34
Volume163.4 K
 

View Biotechnology IndustryPeer Comparison as of 07/13/2020

 

MacroGenics Inc ( NASDAQ )

Price: $30.68
Change: +0.16 (0.52%)
Volume: 163.4 K
1:10PM ET 7/13/2020
 
 

Sangamo Therapeutics Inc ( NASDAQ )

Price: $10.87
Change: +0.18 (1.68%)
Volume: 437.0 K
1:11PM ET 7/13/2020
 
 

Cytokinetics Inc ( NASDAQ )

Price: $25.23
Change: -0.27 (1.06%)
Volume: 199.7 K
1:07PM ET 7/13/2020
 
 

Luminex Corp ( NASDAQ )

Price: $33.43
Change: +0.91 (2.80%)
Volume: 176.4 K
1:13PM ET 7/13/2020
 
 

Epizyme Inc ( NASDAQ )

Price: $15.94
Change: +0.78 (5.15%)
Volume: 452.5 K
1:06PM ET 7/13/2020
 

Read more news Recent News

MacroGenics Says Results of Gastroesophageal Cancer Drug Suggest Improved Clinical Outcomes for Certain Patients
4:15AM ET 7/10/2020 MT Newswires

MacroGenics (MGNX) said Thursday results of a phase 2 study of margetuximab plus pembrolizumab as a chemotherapy-free regimen for patients with advanced...

MacroGenics Names Dr. Stephen Eck as Chief Medical Officer
7:47AM ET 6/16/2020 MT Newswires

MacroGenics (MGNX), a clinical-stage biopharmaceutical company, said premarket Tuesday that it has appointed Dr. Stephen Eck as its chief medical officer,...

Sector Update: Health Care Stocks Flat-to-Higher During Friday's Premarket Trading
9:18AM ET 6/05/2020 MT Newswires

Health care stocks were flat-to-higher during premarket trading on Friday. The Vanguard Health Care ETF (VHT) and the iShares Dow Jones US Healthcare (IYH)...

MacroGenics Wins Orphan Drug Designation For Gastric Cancer Treatment Margetuximab; Shares Up 7% Pre-Bell
8:08AM ET 6/05/2020 MT Newswires

MacroGenics (MGNX) said premarket Friday that margetuximab, the company's investigational monoclonal antibody, has been granted orphan drug designation by...

View all Commentary and Analysis

The Play On MacroGenics
3:43PM ET 7/06/2020 Seeking Alpha

MacroGenics (MGNX) Presents At ASCO 2020 - Slideshow
1:31PM ET 5/29/2020 Seeking Alpha

MacroGenics Reports Data, And Other News: The Good, Bad And Ugly Of Biopharma
9:53AM ET 5/16/2020 Seeking Alpha

Spotlight On Tech Momo, Bitcoin Halving And 13Fs
8:58AM ET 5/09/2020 Seeking Alpha

Company Profile

Business DescriptionMacroGenics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. 2. Its product pipeline includes Margetuximab, Flotetuzumab, Enoblituzumab, MGA012, MGD013, MGD019, MGD009, MGC018, and MGD007 for oncology; and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD. View company web site for more details
Address9704 Medical Center Drive
Rockville, Maryland 20850-3368
Phone+1.301.251.5172
Number of Employees364
Recent SEC Filing07/06/20204
President, Chief Executive Officer & DirectorScott E. Koenig
Chief Financial Officer, Secretary & Senior VPJames Karrels
Chief Scientific Officer & Senior VP-ResearchEzio Bonvini
Chief Medical Officer & SVP-Clinical DevelopmentStephen L. Eck

Company Highlights

Price Open$30.24
Previous Close$30.52
52 Week Range$4.04 - 32.18
Market Capitalization$1.5 B
Shares Outstanding49.1 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement07/29/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$3.21
Beta vs. S&P 500N/A
Revenue$60.1 M
Net Profit Margin-222.14%
Return on Equity-62.43%

Analyst Ratings as of 06/15/2020

Buy
11
Overweight
0
Hold
0
Underweight
0
Sell
2
Consensus RecommendationConsensus Icon
Powered by Factset